Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice

• DOI: 10.1007/s00432-012-1325-9
• Publication Date: 2012-10-09T05:28:52Z
• Authors: Domenico Angelucci; Nicola Tinari; Antonino Grassadonia; Ettore Cianchetti; Giampiero Ausili-...; Laura Iezzi; Marinella Zilli; Simona Grossi; Lucia Anna Ursini; Maria Teresa Scog...; Graziella Castrilli; Michele De Tursi; Paolo Noccioli; Pasquale Cioffi; Stefano Iacobelli; Clara Natoli
• Keywords: Systemic therapy; Hematology; Neoadjuvant Therapy; Clinical Practice

The aim of this study is to evaluate the long-term outcome patients with locally advanced breast cancer treated neoadjuvant systemic chemotherapy (NST) in routine clinical practice.Four hundred and nine were identified between January 1999 December 2011. All received NST followed by surgery, adjuvant treatments radiotherapy, as appropriate.At Kaplan-Meier analysis, surgical stage III disease more likely develop distant metastasis die from (p < 0.001). Luminal A luminal B/HER2-negative had better prognosis; moreover, hormone receptor (HR)-positive tumors a significantly longer DRFS 0.0049) OS 0.0001) compared HR-negative well who underwent breast-conserving surgery (DRFS OS: p In multivariate HR negativity 0.001 for both OS), mastectomy (DRFS: = 0.009; 0.05) 0.001; 0.003) associated shorter OS.HR negativity, pathological are variables independently worse our cohort patients. These data high interest since they derive very heterogeneous group patients, different neoadjuvant/adjuvant regimens outside trials long follow-up period.